Form 4: IOVANCE COO Bilinsky Reports RSU Vesting & Tax Withholding

IOVANCE BIOTHERAPEUTICS Chief Operating Officer Igor Bilinsky reported the vesting of restricted stock units and subsequent share disposals for tax withholding on December 1 and 2, 2025.

Summary

• Igor Bilinsky, Chief Operating Officer of IOVANCE BIOTHERAPEUTICS, reported transactions related to Restricted Stock Units (RSUs).
• On December 1, 2025, 8,789 shares of common stock vested from RSUs.
• Concurrently, 4,464 shares were disposed of at $2.23 per share to cover mandatory tax withholding requirements.
• Following these transactions, beneficial ownership of common stock was 104,014 shares.
• On December 2, 2025, an additional 3,516 shares of common stock vested from RSUs.
• 1,786 shares were disposed of at $2.14 per share for tax withholding purposes.
• After these transactions, beneficial ownership of common stock was 105,744 shares.
• The remaining RSUs from the March 1, 2024 grant are 43,949 units.
• The remaining RSUs from the March 2, 2023 grant are 3,517 units.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to equity compensation, specifically the vesting of Restricted Stock Units and subsequent share disposals for tax purposes. This is a standard event and does not indicate a significant positive or negative shift in company fundamentals or outlook, but confirms ongoing executive equity participation.

Positives

• Vesting of 12,305 Restricted Stock Units (RSUs) demonstrates continued equity participation and alignment of management interests with shareholders.

Negatives

• Disposal of 6,250 shares (4,464 + 1,786) to cover tax withholding requirements, which reduces direct share ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Confirms ongoing alignment of executive compensation with company performance through equity vesting.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Remaining Restricted Stock Units (RSUs) will continue to vest in equal quarterly installments as per the original grant terms.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions involving the vesting of Restricted Stock Units (RSUs) and subsequent share disposals to cover tax obligations. Such transactions are standard for executive equity compensation and do not provide new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions reflect ongoing executive compensation structure rather than a discretionary buy or sell decision based on market outlook.

Keywords

IOVANCE, IOVA, Form 4, Insider Transaction, RSU, Restricted Stock Units, Stock Vesting, Tax Withholding, Igor Bilinsky, Officer Transaction, Equity Compensation